Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

Core Insights - Eli Lilly is reducing the prices of its diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada [1] Company Actions - The price cut is part of a strategy to make these medications more accessible to Canadian consumers [1] - The announcement was communicated to pharmacies through a note issued by the U.S.-based drugmaker [1]